Table 1.

Characteristics of Trials Conducted in the Department of Investigative Cancer Therapeutics at MD Anderson Cancer Center

Study Characteristics	ICT Trials (n=221)
Trial phase designation
Phase I	173 (78%)
Phase I–II	23 (10%)
Phase II	21 (10%)
Phase III	4 (2%)
Trial source
Non-Industry externally funded*	8 (4%)
Industry	133 (60%)
Institution	77 (35%)
National cooperative group	3 (1%)
Trial timeframes: median (IQR), months
Submission to activation	4.3 (3.0–6.0)
Submission to IRB approval	1.2 (1.0–1.8)
IRB approval to activation	2.6 (1.6–4.4)
Activation to first patient enrolled**	0.4 (0.1–1.1)
Trial accrual: median (IQR)
Accrual rate: participants/year	15.3 (9.6–26.1)
Total accrual: participants	30 (12–57)
Trials activated per investigator: median (range)	16 (6–45)

Abbreviations: ICT, investigational cancer therapeutics; IRB, Institutional Review Board; IQR, interquartile range

^*Funding sources include: National Institutes of Health [NIH], Department of Defense [DoD], National Cancer Institute [NCI], and Cancer Therapy Evaluation Program [CTEP].

^**Includes only trials that accrued at least one participant.